Ligand Buys Into Ongoing Partnerships With Icagen Deal
Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.
You may also be interested in...
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.
With Foamix merger closing soon, Menlo’s serlopitant failed a Phase II trial in chronic pruritus of unknown origin, but the firm said a Phase III program in prurigo nodularis shouldn’t be affected. Its share in the new company is contingent on the PN data.